Samit Hirawat
Samit Hirawat's purchase track record
How the stock did after each of Samit Hirawat's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/25/2025 | BMY | $202K | +2.4% | -6.0% | +22.9% |
| 2/14/2025 | BMY | $100K | -12.3% | -8.0% | +5.5% |
| 11/1/2024 | BMY | $100K | +9.7% | -4.9% | -0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Transaction History
| PCRX | ▲ Buy | Grant | 6,405 | $0 | 6/10/2026 | View on chart |
| BMY | ▲ Buy | Open Market | 4,250 | $202K | 4/25/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,886 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 337 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,327 | $147K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,765 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 831 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,013 | $127K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,854 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 998 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,484 | $157K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 28,593 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 10,545 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 9,232 | $583K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Open Market | 1,823 | $100K | 2/14/2025 | View on chart |
| BMY | ▲ Buy | Open Market | 1,830 | $100K | 11/1/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 1,807 | $97K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,885 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,068 | $111K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 29,311 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 9,774 | $526K | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 10,203 | $0 | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,192 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 660 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 842 | $0 | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 9,357 | $0 | 7/1/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 4,787 | $306K | 7/1/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,189 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 775 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,540 | $167K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,885 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 802 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,909 | $191K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,765 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 154 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,517 | $165K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 25,139 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 3,069 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 14,429 | $948K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 9,356 | $0 | 7/1/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 4,786 | $368K | 7/1/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,189 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 553 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,426 | $166K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,885 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 548 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,779 | $190K | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.